One Pager as on August 31, 2024
Agile quality portfolio from India's Big 100 Companies* | |
Exposure to the more stable half of the market | |
High conviction bottom up stock picking with a focus on alpha generation | |
*In terms of Full Market Capitalisation. |
Sector | MMLCF* | Nifty 100 TRI |
Financial Services | 28.61% | 30.74% |
Oil Gas & Consumable Fuels | 13.56% | 10.69% |
Information Technology | 11.92% | 11.36% |
Fast Moving Consumer Goods | 11.35% | 8.88% |
Automobile And Auto Components | 7.02% | 7.71% |
*Mahindra Manulife Large Cap Fund
Data as on August 31, 2024
Security | % to Net Assets |
HDFC Bank Limited | 8.81% |
Reliance Industries Limited | 6.98% |
ICICI Bank Limited | 6.71% |
Infosys Limited | 6.11% |
Larsen & Toubro Limited | 4.41% |
Tata Consultancy Services Limited | 4.34% |
ITC Limited | 3.86% |
Axis Bank Limited | 3.40% |
State Bank of India | 3.33% |
Indus Towers Limited | 3.21% |
Total | 51.16% |
Fresh Additions | Complete Exits |
Security | Security |
Bharat Petroleum Corporation Limited | Gland Pharma Limited |
Page Industries Limited |
Note:
The companies/stock(s) referred above are only for the purpose of disclosure of significant
portfolio changes during the month and should not be construed as recommendation to buy/sell/
hold. The fund manager may or may not choose to hold these companies/stocks, from time to
time. Investors are requested to consult their financial, tax and other advisors before taking any
investment decision(s). Data as on August 31, 2024
Turnover Ratio (Last 1 year) | 0.86 |
Standard Deviation | 12.17% |
Beta | 0.91 |
Sharpe Ratio# | 0.73 |
Jenson's Alpha | 0.0421 |
#Risk-free rate assumed to be 6.80% (MIBOR as on 30-08-24) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling
returns for last 3 years. Data as on August 30, 2024
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 15-Mar-2019.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of
Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Ms. Fatema Pacha is managing this scheme since December 21, 2020.
Mr. Abhinav Khandelwal is managing this scheme since March 1, 2022. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 15-Mar-2019.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business
day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.The performance details provided above are of
Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal manages 6 schemes and
Ms. Fatema Pacha manages 8 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on August 30, 2024.
Note: As August 31, 2024 was a non - business day, the schemes returns disclosed are as on August 30,2024, except for Mahindra Manulife Liquid Fund and Mahindra Manulife Overnight Fund which
is as of August 31, 2024.
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in equity and equity related securities including derivatives of large cap companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.